These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

74 related articles for article (PubMed ID: 2674989)

  • 1. Weekly chemotherapeutic regimen in metastatic prostate cancer.
    Burk K
    Prog Clin Biol Res; 1989; 303():261-75. PubMed ID: 2674989
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Weekly chemotherapeutic regimen in metastatic prostate cancer.
    Burk K
    Prog Clin Biol Res; 1990; 350():187-200. PubMed ID: 2201043
    [TBL] [Abstract][Full Text] [Related]  

  • 3. 9-Nitrocamptothecin as second line chemotherapy for men with progressive, metastatic, hormone refractory prostate cancer: Results of the CALGB 99901.
    Amin A; Halabi S; Gelmann EP; Stadler W; Vogelzang N; Small E
    Urol Oncol; 2004; 22(5):398-403. PubMed ID: 15464920
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Weekly epidoxorubicin therapy in hormone-refractory metastatic prostate cancer.
    Neri B; Barbagli G; Bellesi P; Di Loro R; Lombardi V; Lombardo C; Magrini T; Mottola A; Nicita G; Palminteri E; Ponchietti R; Raugei A; Intini C
    Anticancer Res; 1997; 17(5B):3817-20. PubMed ID: 9427786
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Randomized comparison of total androgen blockade alone versus combined with weekly epirubicin in advanced prostate cancer.
    Pummer K; Lehnert M; Stettner H; Hubmer G
    Eur Urol; 1997; 32 Suppl 3():81-5. PubMed ID: 9267791
    [TBL] [Abstract][Full Text] [Related]  

  • 6. European Organization for Research and Treatment of Cancer (EORTC) phase II study of low-dose weekly epirubicin in metastatic prostate cancer.
    Jones WG; Fosså SD; Bono AV; Klijn JG; De Pauw M; Sylvester R
    Cancer Treat Rep; 1987 Dec; 71(12):1317-8. PubMed ID: 3480046
    [No Abstract]   [Full Text] [Related]  

  • 7. [Metastatic cancer of the prostate: phase II study of spirogermanium (NSC 192965)].
    Bui NB; Chauvergne J; Brunet R; Richaud P; Hoerni B; Lagarde C; Le Guillou M
    Bull Cancer; 1986; 73(1):65-7. PubMed ID: 3779124
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A multi-institutional phase ii study of SU101, a platelet-derived growth factor receptor inhibitor, for patients with hormone-refractory prostate cancer.
    Ko YJ; Small EJ; Kabbinavar F; Chachoua A; Taneja S; Reese D; DePaoli A; Hannah A; Balk SP; Bubley GJ
    Clin Cancer Res; 2001 Apr; 7(4):800-5. PubMed ID: 11309325
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Weekly epirubicin in patients with hormone refractory prostatic cancer--a two-year follow-up.
    Burk K; Schultze-Seemann W; Jonas D; Rodeck G
    Prog Clin Biol Res; 1989; 303():277-85. PubMed ID: 2674990
    [No Abstract]   [Full Text] [Related]  

  • 10. The role of doxorubicin and epirubicin in the treatment of patients with metastatic hormone-refractory prostate cancer.
    Petrioli R; Fiaschi AI; Francini E; Pascucci A; Francini G
    Cancer Treat Rev; 2008 Dec; 34(8):710-8. PubMed ID: 18620815
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evaluation of aminoglutethimide in stage D prostate cancer: an assessment of efficacy and toxicity in patients with tumors refractory to hormonal therapy.
    Block M; Trump D; Rose DP; Cummings KB; Hogan TF
    Cancer Treat Rep; 1984 May; 68(5):719-22. PubMed ID: 6722829
    [No Abstract]   [Full Text] [Related]  

  • 12. [Adjuvant treatment of prostatic carcinoma after primary therapy. The "Early Prostate Cancer" Program].
    Mansueto G; Longo F
    Recenti Prog Med; 2002 Mar; 93(3):175-8. PubMed ID: 11942169
    [No Abstract]   [Full Text] [Related]  

  • 13. Prostate-specific antigen doubling time as a surrogate marker for evaluation of oncologic drugs to treat prostate cancer.
    Kelloff GJ; Coffey DS; Chabner BA; Dicker AP; Guyton KZ; Nisen PD; Soule HR; D'Amico AV
    Clin Cancer Res; 2004 Jun; 10(11):3927-33. PubMed ID: 15173102
    [No Abstract]   [Full Text] [Related]  

  • 14. [Value of mitoxantrone in metastatic hormone-resistant prostate cancer].
    Khalaf A; Pfister C; Hellot MF; Dunet F; Moussu J; Grise P
    Prog Urol; 2002 Feb; 12(1):37-42. PubMed ID: 11980013
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phase II trial of oral uracil/tegafur plus leucovorin in patients with hormone-refractory prostate carcinoma.
    Bhandari MS; Pienta KJ; Fardig J; Olson K; Smith DC
    Cancer; 2006 Apr; 106(8):1715-21. PubMed ID: 16534795
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A Phase I/II study of weekly paclitaxel and 3 days of high dose oral estramustine in patients with hormone-refractory prostate carcinoma.
    Ferrari AC; Chachoua A; Singh H; Rosenthal M; Taneja S; Bednar M; Mandeli J; Muggia F
    Cancer; 2001 Jun; 91(11):2039-45. PubMed ID: 11391583
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Quality of life impact of three different doses of suramin in patients with metastatic hormone-refractory prostate carcinoma: results of Intergroup O159/Cancer and Leukemia Group B 9480.
    Ahles TA; Herndon JE; Small EJ; Vogelzang NJ; Kornblith AB; Ratain MJ; Stadler W; Palchak D; Marshall ME; Wilding G; Petrylak D; Holland JC;
    Cancer; 2004 Nov; 101(10):2202-8. PubMed ID: 15484217
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Cycloplatam in the treatment of patients with disseminated prostatic cancer].
    Matveev BP; Gorbunova VA; Smirnova NB; Zhumagazin ZhD; Bukharkin BV; Orel NF
    Urol Nefrol (Mosk); 1996; (3):34-6. PubMed ID: 8928330
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Preliminary results of casodex use in patients with hormone-resistant cancer of the prostate].
    Matveev BP; Bukharkin BV
    Urologiia; 2001; (6):20-1. PubMed ID: 11785074
    [No Abstract]   [Full Text] [Related]  

  • 20. Novel therapeutic strategies in prostate cancer: establishing a stratification system for patient selection in targeted trials.
    Priolo C; Oh WK; Loda M
    IDrugs; 2009 Mar; 12(3):165-8. PubMed ID: 19333896
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.